<DOC>
	<DOCNO>NCT00601250</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability BI 1356 ( 5 mg daily ) compare placebo give 24 week add-on therapy metformin patient type 2 diabetes mellitus insufficient glycaemic control</brief_summary>
	<brief_title>Efficacy Safety B I1356 ( Linagliptin ) v . Placebo Added Metformin Background Therapy Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient diagnosis type 2 diabetes mellitus previously treat metformin alone , metformin one oral antidiabetic drug 2 . Diagnosis type 2 diabetes prior inform consent 3 . Glycosylated haemoglobin A1 ( HbA1c ) screening : For patient undergo wash previous medication : HbA1c 6.5 9.0 % For patient undergo washout previous medication : HbA1c 7.0 10.0 % 4 . Glycosylated haemoglobin A1 ( HbA1c ) 7.0 10.0 % begin Placebo Runin 5 . Age 18 80 year 6 . BMI ( Body Mass Index ) less 40 kg/m2 7 . Signed date write informed consent date Visit 1a accordance GCP local legislation Exclusion criterion : 1 . Myocardial infarction , stroke transient ischemic attack ( TIA ) within 6 month prior inform consent 2 . Impaired hepatic function 3 . Known hypersensitivity allergy investigational product excipients metformin placebo 4 . Treatment rosiglitazone pioglitazone within 3 month prior inform consent 5 . Treatment injectable GLP1 analogue ( e.g . exenatide ) within 3 month prior inform consent 6 . Treatment insulin within 3 month prior inform consent 7 . Treatment antiobesity drug ( e.g . sibutramine , orlistat , rimonabant ) within 3 month prior inform consent 8 . Alcohol abuse within 3 month prior inform consent would interfere trial participation drug abuse 9 . Participation another trial investigational drug within 2 month prior inform consent 10 . Premenopausal woman : nursing pregnant , childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . 11 . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent . 12 . Renal failure renal impairment 13 . Unstable acute congestive heart failure 14 . Acute chronic metabolic acidosis ( present patient history ) 15 . Hereditary galactose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>